Analysts Set PRA Health Sciences Inc (PRAH) PT at $111.50

Shares of PRA Health Sciences Inc (NASDAQ:PRAH) have been assigned an average rating of “Buy” from the thirteen ratings firms that are covering the stock, Marketbeat reports. Two analysts have rated the stock with a hold recommendation and ten have given a buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $111.50.

A number of equities research analysts recently issued reports on the company. BidaskClub lowered PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Friday, November 16th. SunTrust Banks upped their target price on PRA Health Sciences to $120.00 and gave the company a “buy” rating in a research note on Monday, November 5th. UBS Group assumed coverage on PRA Health Sciences in a research note on Tuesday, October 9th. They issued a “neutral” rating on the stock. Evercore ISI assumed coverage on PRA Health Sciences in a research note on Thursday, October 4th. They issued an “inline” rating and a $120.00 target price on the stock. Finally, Robert W. Baird upped their target price on PRA Health Sciences from $112.00 to $116.00 and gave the company an “outperform” rating in a research note on Tuesday, September 11th.

Shares of PRAH traded up $1.97 on Friday, reaching $103.28. The stock had a trading volume of 797 shares, compared to its average volume of 447,855. The stock has a market cap of $6.58 billion, a P/E ratio of 32.11, a P/E/G ratio of 1.47 and a beta of 0.73. The company has a debt-to-equity ratio of 1.22, a current ratio of 0.89 and a quick ratio of 0.89. PRA Health Sciences has a twelve month low of $79.00 and a twelve month high of $112.88.

PRA Health Sciences (NASDAQ:PRAH) last released its quarterly earnings results on Wednesday, October 31st. The medical research company reported $1.13 earnings per share for the quarter, topping analysts’ consensus estimates of $1.07 by $0.06. The business had revenue of $717.60 million for the quarter, compared to analysts’ expectations of $729.63 million. PRA Health Sciences had a return on equity of 25.75% and a net margin of 2.37%. The company’s revenue was up 23.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.88 EPS. Research analysts expect that PRA Health Sciences will post 3.93 EPS for the current fiscal year.

Several institutional investors have recently modified their holdings of the business. Carnegie Capital Asset Management LLC lifted its stake in shares of PRA Health Sciences by 0.9% during the 2nd quarter. Carnegie Capital Asset Management LLC now owns 59,966 shares of the medical research company’s stock worth $6,083,000 after purchasing an additional 556 shares during the period. Strs Ohio raised its position in shares of PRA Health Sciences by 14.2% in the 3rd quarter. Strs Ohio now owns 4,582 shares of the medical research company’s stock worth $504,000 after buying an additional 569 shares during the period. Bank of Montreal Can raised its position in shares of PRA Health Sciences by 12.8% in the 3rd quarter. Bank of Montreal Can now owns 6,491 shares of the medical research company’s stock worth $715,000 after buying an additional 738 shares during the period. Twin Tree Management LP raised its position in shares of PRA Health Sciences by 59.7% in the 3rd quarter. Twin Tree Management LP now owns 2,058 shares of the medical research company’s stock worth $227,000 after buying an additional 769 shares during the period. Finally, MML Investors Services LLC raised its position in shares of PRA Health Sciences by 34.7% in the 3rd quarter. MML Investors Services LLC now owns 3,006 shares of the medical research company’s stock worth $331,000 after buying an additional 774 shares during the period.

About PRA Health Sciences

PRA Health Sciences, Inc, a contract research organization, provides outsourced clinical development services to the biotechnology and pharmaceutical industries worldwide. The company operates in two segments, Clinical Research and Data Solutions. The Clinical Research segment offers product registration services, including clinical trial management, project management, regulatory affairs, therapeutic expertise, clinical operations, data and programming, safety and risk management, biostatistics and medical writing, quality assurance, and late phase services.

Featured Story: Understanding Average Daily Trade Volume

Analyst Recommendations for PRA Health Sciences (NASDAQ:PRAH)

Receive News & Ratings for PRA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply